COMPANY OVERVIEW

NeuroproteXeon, Inc. is a clinical-stage pharmaceutical/device company developing xenon to improve functional capabilities and survival in patients with Post-Cardiac Arrest Syndrome ("PCAS").

---

LOCATION

Orchard Park, NY, USA

---

THERAPEUTIC AREAS

Cardiovascular Disease

Neurological DIsorders

---

WEBSITE

https://neuroprotexeon.com/npx/

---

CAREER WEBSITE

https://neuroprotexeon.com/npx/join-us/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

May 9, 2018

European Distribution Partnership between NeuroproteXeon and Linde

Nov 28, 2017

NeuroproteXeon Announces Publication of Xenon Study to Lessen Cardiac Damage Following Out-of-Hospital Cardiac Arrest ("OHCA")

For More Press Releases

---